Purple Biotech Reports Q4 Non-GAAP EPS of $19.85 Amid Increased Losses

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: Mar 13 2026

0mins

PPBT-6.99%

Should l Buy PPBT?

Source: seekingalpha

Widening Financial Losses: Purple Biotech reported an operating loss of $23.4 million in Q4, an increase of $22.4 million compared to the same period in 2024, primarily due to $20.5 million in non-cash impairment expenses recognized during the period, indicating significant R&D expenditures.
Adjusted Operating Loss: The adjusted operating loss was $2.9 million, up from $1.0 million in the same period of 2024, primarily reflecting increased activities in the CAPTN-3 platform development, showcasing the company's ongoing investment in new product development.
Significant Net Loss: The net loss reached $23.6 million, a substantial increase of $23.1 million compared to $0.4 million in 2024, largely driven by the $20.5 million non-cash impairment expenses, highlighting the growing financial pressures faced by the company.
Cash Flow Status: As of December 31, 2025, Purple Biotech had cash and cash equivalents totaling $9.5 million, which is expected to provide a cash runway into 2027, despite ongoing financial challenges.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy PPBT?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on PPBT

Wall Street analysts forecast PPBT stock price to rise

1 Analyst Rating

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 3.725

Low

34.00

Averages

34.00

High

34.00

Current: 3.725

Low

34.00

Averages

34.00

High

34.00

H.C. Wainwright

Emily Bodnar

Buy

downgrade

$34 -> $30

2026-03-13

Reason

H.C. Wainwright

Emily Bodnar

Price Target

$34 -> $30

AI Analysis

2026-03-13

downgrade

Buy

Reason

H.C. Wainwright analyst Emily Bodnar lowered the firm's price target on Purple Biotech to $30 from $34 and keeps a Buy rating on the shares. The company reported Q4 earnings and provided a corporate update, highlighting recent progress for the company's preclinical CAPTN-3 tri-specific T cell engager programs, the analyst tells investors in a research note. The firm said it expects additional updates regarding progress of the investigational new drug submission and plans for Phase 1 throughout 2026. The firm added that its new price target is based on a discounted cash flow analysis.

About PPBT

Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Purple Biotech Partners with Converge Bio to Enhance Development of Next-Generation Tri-Specific Antibody Platform Using AI

6 days agomoomoo

Collaboration Announcement: Purple Biotech has announced a collaboration with Converge Bio to enhance the development of its next-generation tri-specific antibody platform.
Focus on Accelerated Development: The partnership aims to accelerate the development process of innovative therapeutic solutions using advanced antibody technology.

Purple Biotech Regains Nasdaq Compliance

Mar 17 2026seekingalpha

Compliance Restoration: Purple Biotech confirmed on March 13, 2026, that it has regained compliance with Nasdaq rules, maintaining a minimum closing bid price of $1.00 per ADS for at least 10 consecutive business days, ensuring its continued listing on the Nasdaq Capital Market.
Market Reaction: This compliance restoration may boost investor confidence and improve the company's stock performance, especially after facing compliance risks, potentially enhancing market expectations for its future development.
Financial Performance: Purple Biotech reported a Non-GAAP EPS of $19.85, indicating strong profitability, which further solidifies its market position in the biotechnology sector.
Future Outlook: With compliance issues resolved, Purple Biotech can focus more on its R&D and market expansion strategies, which is expected to drive long-term growth potential in the biopharmaceutical industry.